PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 2026Nano Select0 citationsOpen Access

Smart Polymer‐Based Drug Delivery Systems for Managing Infective Conjunctivitis: Advances and Future Prospects

View Full Paper
XLXia LinkangMMMarwan Abdelmahmoud Abdelkarim MakiSTSaad Tayyab

Key Points

  • The aim is to explore the advancements in smart polymer-based systems for improving treatments for infective conjunctivitis.
  • Review of nanocarrier technologies including liposomes, nanoparticles, and dendrimers.
  • Analysis of stimuli-responsive polymer features like pH sensitivity and thermosensitivity.
  • Evaluation of safety, efficacy, and biocompatibility through preclinical and clinical studies.
  • Smart polymers enable controlled drug release, enhancing bioavailability and therapeutic efficiency.
  • Nanotechnology approaches lower systemic side effects and improve patient compliance.
  • Studies demonstrate the safety and effectiveness of these systems in treating infective conjunctivitis.

Abstract

ABSTRACT Nanotechnology‐based smart polymer delivery systems are transforming the treatment of infective conjunctivitis, a common ocular condition caused by bacterial or viral infections. Conventional therapies often suffer from poor bioavailability and limited patient compliance, largely due to the eye's protective mechanisms that rapidly clear administered drugs. Nanocarriers, such as liposomes, nanoparticles, dendrimers, and nanogels, offer innovative solutions for targeted and effective drug delivery. Integration of smart polymers further enhances therapeutic efficiency by responding to environmental triggers, including pH, temperature, or enzymatic activity, enabling controlled and sustained drug release. This review emphasizes the role of stimuli‐responsive polymers, including pH‐sensitive, thermosensitive, and mucoadhesive systems, in optimizing drug delivery to infected or inflamed ocular tissues. These advanced platforms minimize systemic side effects, improve patient compliance, human health and enhance therapeutic outcomes. Preclinical and clinical studies support safety, efficacy, and biocompatibility of these nanotechnology‐based approaches and highlighting their potential advancement in ocular drug delivery for the management of infective conjunctivitis and broader ophthalmic applications.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Linkang et al. (2026) studied this question.

synapsesocial.com/papers/6a1d22f702fbce9130638950https://doi.org/10.1002/nano.70110
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nano-based ocular drug delivery systems: an insight into the preclinical/clinical studies and their potential in the treatment of posterior ocular diseases2023 · 32 citations
  2. 2Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier2011 · 4,722 citations
  3. 3Dendrimers: Exploring Their Wide Structural Variety and Applications2023 · 167 citations
  4. 4Polymer-Based Hydrogels Applied in Drug Delivery: An Overview2023 · 792 citations
  5. 5Functional Thermoresponsive Hydrogel Molecule to Material Design for Biomedical Applications2022 · 98 citations